6 August 2020 in Current Opinion in Endocrinology, Diabetes and Obesity
Purpose of review: Ketogenic diets, which have been used to treat drug-refractory paediatric epilepsy for over 100 years, are becoming increasingly popular for the treatment of other neurological conditions, including mental illnesses. We aim to explain how ketogenic diets can improve mental illness biopathology and review the recent clinical literature. Recent findings: Psychiatric conditions, such as schizophrenia, depression, bipolar disorder and binge eating disorder, are neurometabolic diseases that share several common mechanistic biopathologies. These include glucose hypometabolism, neurotransmitter imbalances, oxidative stress and inflammation. There is strong evidence that ketogenic diets can address these four fundamental diseases, and now complementary clinical evidence that ketogenic diets can improve the patients’ symptoms. Summary: It is important that researchers and clinicians are made aware of the trajectory of the evidence for the implementation of ketogenic diets in mental illnesses, as such a metabolic intervention provides not only a novel form of symptomatic treatment, but one that may be able to directly address the underlying disease mechanisms and, in so doing, also treat burdensome comorbidities (see Video, Supplementary Digital Content 1, http://links.lww.com/COE/A16, which summarizes the contents of this review).
1 June 2019 in Schizophrenia Research
1 November 2017 in Schizophrenia Research
23 June 2020 in International Journal of Neuropsychopharmacology
21 November 2024 in Current Treatment Options in Psychiatry
Purpose of Review This review explores the evidence for using a ketogenic diet as a transdiagnostic treatment for mental health disorders. We examine the biological pathophysiologic mechanisms that underlie many neuropsychiatric disorders—such as mitochondrial dysfunction, oxidative stress, inflammation, glucose hypometabolism, and glutamate/GABA imbalance—that can be ameliorated by the ketogenic diet. Additionally, a literature review summarizes clinical trials and case reports on the ketogenic diet as a treatment for various psychiatric disorders. Recent Findings Recent research provides evidence that the ketogenic diet may be an effective treatment for schizophrenia/schizoaffective disorder, bipolar disorder, depression, anxiety disorders, Alzheimer’s disease, autism spectrum disorder, somatic disorders, eating disorders, and alcohol use disorder. Summary Many psychiatric disorders have shared metabolic pathways that exacerbate or cause psychopathology. The ketogenic diet is a transdiagnostic treatment that can not only address metabolic dysfunction, but can also ameliorate symptoms like depression, anxiety, mania, psychosis, and cognitive impairment. These effects suggest that the diet has the potential to serve as a non-pharmacological treatment option and ease the global disease burden of neuropsychiatric disorders.
28 May 2024 in Current Treatment Options in Psychiatry
VCVirginie-Anne Chouinard
Purpose of Review: The ketogenic diet is a low carbohydrate, moderate protein, and high fat diet which results in a metabolic state known as ketosis, in which fats are broken down into ketone bodies. The ketogenic diet is a 100-year-old evidence-based treatment for epilepsy and is gaining popularity as a treatment for various mental disorders, including mood disorders. Our objective is to explain the potential mechanisms through which ketogenic diets may improve the pathophysiology of mood disorders and provide a comprehensive review of recent clinical literature on the topic Recent Findings: Mood disorders are associated with several proposed pathophysiological mechanisms, including mitochondrial dysfunction, oxidative stress, inflammation, and insulin resistance. The ketogenic diet shows promise in addressing these underlying pathophysiological mechanisms and emerging clinical data suggest that ketogenic diets may improve symptoms in people with mood disorders. Summary: The ketogenic diet shows promise in the treatment of mood disorders. This metabolic intervention has the potential to directly target underlying disease mechanisms, potentially reduce the need for medications, and reduce common side effects and comorbidities, such as weight gain and insulin resistance.